PURPOSE: Activating Flt3 mutations are observed in about 30% of patients with acute myeloid leukaemia (AML) and individual Flt3 mutations are applicable for minimal residual disease (MRD) analyses. METHODS: We investigated the MRD status in four AML patients carrying different Flt3 mutations (three patients with Flt3 length mutations of the juxtamembrane domain, one patient carrying a mutation of the Flt3 tyrosine kinase domain, i.e. Flt3-TKD mutation) who underwent allogeneic peripheral blood stem cell transplantation (PBSCT). Residual leukaemia cells were retrospectively determined by real-time PCR at different time points. RESULTS: We can demonstrate a good correlation between the course of MRD status and clinical events in all four investigated patients. CONCLUSION: These examples demonstrate the potential impact of Flt3 based MRD status not only after but also prior to allogeneic PBSCT.
PURPOSE: Activating Flt3 mutations are observed in about 30% of patients with acute myeloid leukaemia (AML) and individual Flt3 mutations are applicable for minimal residual disease (MRD) analyses. METHODS: We investigated the MRD status in four AMLpatients carrying different Flt3 mutations (three patients with Flt3 length mutations of the juxtamembrane domain, one patient carrying a mutation of the Flt3 tyrosine kinase domain, i.e. Flt3-TKD mutation) who underwent allogeneic peripheral blood stem cell transplantation (PBSCT). Residual leukaemia cells were retrospectively determined by real-time PCR at different time points. RESULTS: We can demonstrate a good correlation between the course of MRD status and clinical events in all four investigated patients. CONCLUSION: These examples demonstrate the potential impact of Flt3 based MRD status not only after but also prior to allogeneic PBSCT.
Authors: Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: Y Yamamoto; H Kiyoi; Y Nakano; R Suzuki; Y Kodera; S Miyawaki; N Asou; K Kuriyama; F Yagasaki; C Shimazaki; H Akiyama; K Saito; M Nishimura; T Motoji; K Shinagawa; A Takeshita; H Saito; R Ueda; R Ohno; T Naoe Journal: Blood Date: 2001-04-15 Impact factor: 22.113
Authors: P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch Journal: Blood Date: 2001-09-15 Impact factor: 22.113
Authors: S Slavin; A Nagler; E Naparstek; Y Kapelushnik; M Aker; G Cividalli; G Varadi; M Kirschbaum; A Ackerstein; S Samuel; A Amar; C Brautbar; O Ben-Tal; A Eldor; R Or Journal: Blood Date: 1998-02-01 Impact factor: 22.113
Authors: M Nakao; S Yokota; T Iwai; H Kaneko; S Horiike; K Kashima; Y Sonoda; T Fujimoto; S Misawa Journal: Leukemia Date: 1996-12 Impact factor: 11.528
Authors: Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Homer A Macapinlac; Homer Macapintac; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne Journal: Biol Blood Marrow Transplant Date: 2010-06-14 Impact factor: 5.742
Authors: Michael R Grunwald; Li-Hui Tseng; Ming-Tseh Lin; Keith W Pratz; James R Eshleman; Mark J Levis; Christopher D Gocke Journal: Biol Blood Marrow Transplant Date: 2014-08-23 Impact factor: 5.742
Authors: Ming-Tseh Lin; Li-Hui Tseng; Jonathan C Dudley; Stacey Riel; Harrison Tsai; Gang Zheng; Keith W Pratz; Mark J Levis; Christopher D Gocke Journal: Mol Diagn Ther Date: 2015-12 Impact factor: 4.074